Background

Nexstim plc, headquartered in Helsinki, Finland and listed on both Nasdaq First North Finland and Nasdaq First North Sweden, is a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim’s NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain. The NBS system has been sold to approximately 140 research universities and leading hospitals in the world.

Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked for the treatment of stroke, major depression and chronic neuropathic pain. Nexstim expects to file for FDA clearance in April 2018 for NBT’s use in the rehabilitation of hand and arm movement which is the most common symptom following stroke.

About Navigated Brain Stimulation NBS

Nexstim’s NBS System combines non-invasive Transcranial Magnetic Stimulation (TMS) with unique proprietary electric field modelling-based navigational capabilities. A magnetic field induces an electric field in the brain leading to neuronal activation. Navigation is a key differentiator and competitive advantage in terms of its accuracy, repeatability and precise dosing capabilities.

A solid solution platform

- The NBS System combines Magnetic Resonance Imaging (MRI-based imaging) guidance with non-invasive TMS and Electromyography (EMG) measurement for response measurement
- System integration, proprietary e-field algorithms and 3D visualisation provide unrivalled accuracy of targeting stimulation
- The device has demonstrated a 46% increase in progression free survival in low grade gliomas versus the current invasive gold standard.

Focus

Development of world leading image-guided transcranial magnetic stimulation (TMS) through Navigated Brain Therapy (NBT®) and Navigated Brain Stimulation (NBS), aiming to drastically improve the quality of life of patients.

Management

Martin Jamieson
Chief Executive Officer

Mikko Karvinen
Chief Financial Officer

Founded

25 October 2000

Address

Nexstim Plc
Elimäenkatu 9 B
FI-00510 Helsinki
Finland
Tel. +358 9 2727 1710
www.nexstim.com

Investor and Media Relations

Citigate Dewe Rogerson
Katja Stout
Tel: +44 20 7 282 1066
Email: nexstim@citigatedr.co.uk
Working to Gain NBT’s US Approval for Stroke

Nexstim has commenced its supplementary E-FIT (ELECTRIC FIELD NAVIGATED 1HZ RTMS FOR POST-STROKE MOTOR RECOVERY TRIAL) for its NBT® system in stroke. The trial will be conducted at five clinical sites (listed above) in the U.S.A. and include 60 subjects. This data will be pooled with the previous Phase III NICHE trial data of 173 patients at 12 leading US centres which showed excellent results in the active group. Nexstim expects to obtain positive results from the E-FIT trial following its completion at the end of Q1 2018 and to file for FDA de novo clearance in April 2018. FDA clearance will allow Nexstim to start marketing and selling its NBT system for stroke rehabilitation in the USA. The NBT® system is already CE marked for stroke rehabilitation in Europe.

About Navigated Brain Therapy NBT®

The Navigated Brain Therapy (NBT®) System is a device that uses navigated transcranial magnetic stimulation (nTMS) for multiple uses, including stroke rehabilitation, depression and chronic pain. Navigation is achieved by visualising the electric field (e-field) generated by the TMS in a 3D image rendered from the patient’s MRI scan. Stimulation intensity is calculated from the accurate measurement of brain excitability and the personal resting motor threshold (MT) of each patient. The proven accuracy confirms optimal treatment location for the individual patient, and ensures that stimulation treatment is always repeated at the same location, every time and for every session.

In stroke therapy, using a patient’s own MRI scan as a guide, Nexstim provides precisely targeted, personalised, magnetic stimulation to temporarily inhibit the healthy side of the brain, normalising the balance between the hemispheres. Because the injured side is no longer dominated by the healthy side of the brain, it is more responsive to the physiotherapy. This results in limb movement being potentially restored more quickly to better functionality.

Market Size

4.5m

New cases of stroke each year in the US, Europe and China

50% of stroke patients suffer from upper limb paralysis

Focus on the period over 3 months post stroke

Annual market size USD 1.8 billion (EU and US)